drugset / Trial / NCT00308048

14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

NCT00308048

RandomizedParallel-groupOpen-labelTreatment

Summary

Patients with HCV genotype 2 or 3 infection who have a rapid virological response to treatment are randomised to either 14 or 24 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.

Timeline

Start
2004-03
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2b Protein / enzyme biologic 1.5 ug/kg
Subject Ribavirin Small molecule 800 mg
Subject Ribavirin Small molecule 1400 mg